Company intelligence / Profile preview

Auditus

United States

Ownership: Private
Development stage: Other

Overview

Auditus's pharmaceutical partner previously led a successful Phase 1 clinical trial in 2015 to demonstrate safety of NHPN-1010[1]. The company discovered the drug's ability to regenerate and reconnect damaged nerve endings on surviving hair cells, which was once thought to be irreversible[1]. As of February 2020, Oblato was expected to initiate Phase 2 clinical trials to evaluate the drug's potential to prevent and treat hearing loss, with follow-up studies potentially testing efficacy for tinnitus and improving speech intelligibility in noise[1].

Therapeutic areas: Neurology
Modalities: Small molecule
Industry: Biotech

Partnerships

Hough Ear Institute (HEI)Oklahoma Medical Research Foundation (OMRF)Oblato Inc.

Beyond the preview

Go deeper on Auditus.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Auditus.

Explore the full profile